In vitro safety pharmacology profiling

Russell Publishing Ltd
Court Lodge
Hogtrough Hill
Brasted
Kent TN16 1NU. UK
Registered in England
No. 2709148
Registered office as above.
VAT No. GB 577 897847

You are here: Home » Drug Safety » In vitro safety pharmacology profiling

publication date: Feb 2, 2006

One major cause of the late failure of drugs in development (i.e. attrition) is the lack of clinical safety of the compounds (accounting for approximately 30% of failures together with toxicology). One of the key elements is the off-target effects of the compounds, causing adverse drug reaction (ADRs).

Sorry, this page is available to members only.

If you have not registered with us yet, why not register today for FREE and receive exclusive online access. Interested in receiving European Pharmaceutical Review in print? Subscribe today and guarantee the next six issues delivered direct to your desk, plus gain exclusive access online.

Why should I register online with European Pharmaceutical Review?

You will receive . . .

* Up to date information on all latest technologies in drug development and manufacturing

* Exciting new features, interviews, updates and profiles

* All latest developments, news and innovations

* Information on projects that your industry colleagues are involved in

* Exclusive access our back issue archive

Click here to join